An oncolytic adenovirus co-expressing a bi-specific T cell engager and IL-2 for the treatment of ovarian cancer

Mol Ther. 2024 Sep 4;32(9):2810-2813. doi: 10.1016/j.ymthe.2024.08.007. Epub 2024 Aug 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenoviridae* / genetics
  • Animals
  • Cell Line, Tumor
  • Female
  • Genetic Therapy / methods
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • Humans
  • Interleukin-2* / genetics
  • Interleukin-2* / metabolism
  • Mice
  • Oncolytic Virotherapy* / methods
  • Oncolytic Viruses* / genetics
  • Oncolytic Viruses* / immunology
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / immunology
  • Ovarian Neoplasms* / therapy
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Interleukin-2